Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Heart Failure Dialysis Patients
NCT05967156Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in heart failure (HF), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Brain Natriuretic Peptide at 1 month. Started Jun 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05967156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967156.